Mast cell activation syndromes presenting as anaphylaxis

Immunology and Allergy Clinics of North America

Volumn 35, Issue 2, 2015, Pages 277-285

  Akin, Cem ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anaphylaxis; Mast cell activation syndrome; Mast cells; Mastocytosis; Tryptase

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ADRENALIN; ALPHA INTERFERON; CLADRIBINE; CROMOGLYCATE DISODIUM; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; INSECT VENOM; INTERLEUKIN 2 RECEPTOR ALPHA; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; N METHYLHISTAMINE; OMALIZUMAB; PROSTAGLANDIN D2; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; TRYPTASE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BONE MARROW BIOPSY; DESENSITIZATION; DISEASE CLASSIFICATION; FAINTNESS; GENE MUTATION; HUMAN; HYMENOPTERA; HYPOTENSION; IMMUNOTHERAPY; MAST CELL; MAST CELL ACTIVATION SYNDROME; MASTOCYTOSIS; MONOCLONAL MAST CELL ACTIVATION SYNDROME; ONCOGENE C KIT; PRIORITY JOURNAL; REVIEW; SYSTEMIC DISEASE; URTICARIA; URTICARIA PIGMENTOSA; VENOM IMMUNOTHERAPY; CLONAL EVOLUTION; DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; IMMUNOLOGY; SYNDROME;

ANAPHYLAXIS; CLONAL EVOLUTION; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; IMMUNOGLOBULIN E; MAST CELLS; MASTOCYTOSIS; SYNDROME;

EID: 84926326685     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2015.01.010     Document Type: Review

References (41)

1. Reber L.L., Marichal T., Galli S.J. New models for analyzing mast cell functions invivo. Trends Immunol 2012, 12:613.
2. Akin C., Valent P., Metcalfe D.D. Mast cell activation syndrome: proposed diagnostic criteria. JAllergy Clin Immunol 2010, 126:1099.
3. Jennings S., Russell N., Jennings B., et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. JAllergy Clin Immunol Pract 2014, 2:70.
4. Akin C., Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am 2014, 34:207.
5. Jensen B.M., Metcalfe D.D., Gilfillan A.M. Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation. Inflamm Allergy Drug Targets 2007, 6:57.
6. Bougherara H., Subra F., Crépin R., et al. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res 2009, 7:1525.
7. Saleh R., Wedeh G., Herrmann H., et al. Anew human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. Blood 2014, 124:111.
8. Fried A.J., Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013, 13:693.
9. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603.
10. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. JMol Diagn 2006, 8:412.
11. Kristensen T., Vestergaard H., Møller M.B. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. JMol Diagn 2011, 13:180.
12. Teodosio C., García-Montero A.C., Jara-Acevedo M., et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012, 26:951.
13. Sotlar K., Horny H.P., Simonitsch I., et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28:1319.
14. Doyle L.A., Sepehr G.J., Hamilton M.J., et al. Aclinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol 2014, 38:832.
15. Akin C., Scott L.M., Kocabas C.N., et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007, 110:2331.
16. Sonneck K., Florian S., Müllauer L., et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007, 142:158.
17. Greenhawt M., Akin C. Mastocytosis and allergy. Curr Opin Allergy Clin Immunol 2007, 7:387.
18. Brockow K., Jofer C., Behrendt H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63:226.
19. Matito A., Alvarez-Twose I., Morgado J.M., et al. Anaphylaxis as a clinical manifestation of clonal mast cell disorders. Curr Allergy Asthma Rep 2014, 14:450.
20. Ruëff F., Przybilla B., Biló M.B., et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. JAllergy Clin Immunol 2009, 124:1047.
21. Bonadonna P., Perbellini O., Passalacqua G., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. JAllergy Clin Immunol 2009, 123:680.
22. Wagner N., Fritze D., Przybilla B., et al. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Immunol 2008, 146:162.
23. Oude Elberink J.N., de Monchy J.G., Kors J.W., et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. JAllergy Clin Immunol 1997, 99:153.
24. Cifuentes L., Ring J., Brockow K. Clonal mast cell activation syndrome with anaphylaxis to sulfites. Int Arch Allergy Immunol 2013, 162:94.
25. Brockow K., Bonadonna P. Drug allergy in mast cell disease. Curr Opin Allergy Clin Immunol 2012, 12:354.
26. Dewachter P., Castells M.C., Hepner D.L., et al. Perioperative management of patients with mastocytosis. Anesthesiology 2014, 120:753.
27. Gülen T., Hägglund H., Dahlén B., et al. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clin Exp Allergy 2014, 44:121.
28. Alvarez-Twose I., González de Olano D., Sánchez-Muñoz L., et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. JAllergy Clin Immunol 2010, 125:1269.
29. van Doormaal J.J., van der Veer E., van Voorst Vader P.C., et al. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. Allergy 2012, 67:683.
30. Valent P., Akin C., Arock M., et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012, 157:215.
31. Luna-Gomes T., Magalhães K.G., Mesquita-Santos F.P., et al. Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation. JImmunol 2011, 187:6518.
32. Siebenhaar F., Akin C., Bindslev-Jensen C., et al. Treatment strategies in mastocytosis. Immunol Allergy Clin North Am 2014, 34:433.
33. Ditto A.M., Harris K.E., Krasnick J., et al. Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol 1996, 77:285.
34. Kettelhut B.V., Berkebile C., Bradley D., et al. Adouble-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. JAllergy Clin Immunol 1989, 83:866.
35. Ravi A., Butterfield J., Weiler C.R. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. JAllergy Clin Immunol Pract 2014, 2:775.
36. Carter M.C., Robyn J.A., Bressler P.B., et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. JAllergy Clin Immunol 2007, 119:1550.
37. Sokol K.C., Ghazi A., Kelly B.C., et al. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. JAllergy Clin Immunol Pract 2014, 2:266.
38. Bell M.C., Jackson D.J. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 2012, 108:383.
39. Valent P., Sperr W.R., Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010, 116:5812.
40. Butterfield J.H., Weiler D., Dewald G., et al. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988, 12:345.
41. Kirshenbaum A.S., Akin C., Wu Y., et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 2003, 27:677.